Related references
Note: Only part of the references are listed.Protein kinases PknA and PknB independently and coordinately regulate essential Mycobacterium tuberculosis physiologies and antimicrobial susceptibility
Jumei Zeng et al.
PLoS Pathogens (2020)
Development of Macozinone for TB treatment: An Update
Vadim Makarov et al.
APPLIED SCIENCES-BASEL (2020)
Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity
M. R. Manjunatha et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity
Qiang Feng et al.
MOLECULAR DIVERSITY (2019)
Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169)
Andreanne Lupien et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Identification of KasA as the cellular target of an anti-tubercular scaffold
Katherine A. Abrahams et al.
NATURE COMMUNICATIONS (2016)
DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization
Miroslav Brecik et al.
ACS CHEMICAL BIOLOGY (2015)
Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values
Marta Tato et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2014)
Mycobacterial Gene cuvA Is Required for Optimal Nutrient Utilization and Virulence
Mushtaq Mir et al.
INFECTION AND IMMUNITY (2014)
Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents
Pravin S. Shirude et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
Alimuddin I. Zumla et al.
LANCET INFECTIOUS DISEASES (2014)
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Vadim Makarov et al.
SCIENCE (2009)
Share Paper
